Description: Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Home Page: www.sanofi.com
46, avenue de la Grande Armée,
Paris,
75017
France
Phone:
33 1 53 77 40 00
Officers
Name | Title |
---|---|
Mr. Paul Hudson | CEO & Director |
Mr. François-Xavier Roger | Executive VP & CFO |
Ms. Madeleine Roach | Executive VP & Head of Business Operations |
Mr. Laurent Gilhodes | Principal Accounting Officer and Vice President of Corporate Accounting |
Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care |
Mr. Thomas Kudsk Larsen | Head of Investor Relations |
Mr. Dante Beccaria | Global Compliance Officer & VP |
Mr. Roy Papatheodorou | Executive VP & General Counsel |
Mr. Josep Catlla | Head of Communications |
Mr. Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 10.3199 |
---|---|
Trailing PE: | 25.0663 |
Price-to-Book MRQ: | 1.5512 |
Price-to-Sales TTM: | 2.5058 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 86088 |